Jefferies backs AstraZeneca's sales ambition, noting Baxfendy for hypertension and tozorakimab as a potential COPD treatment.
1 report, 1 independent
Updated Wed 16:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies backs AstraZeneca's sales ambition, noting Baxfendy for hypertension and tozorakimab as a potential COPD treatment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company